Substrate dependence of the postischemic cardiomyocyte recovery: dissociation between functional, metabolic and injury markers.
Defining the substrate that influences the most favourably the myocardial post-ischemic recovery is subject of debates, due to dissociation between functional and biochemical benefits. Hence, we studied the effects of either glucose or different fatty acids on the functional and metabolic recovery of post-ischemic cardiomyocytes in a substrate-free hypoxia model of simulated ischemia-reperfusion. Rat cardiomyocytes were submitted to a 2.5 h simulated ischemia followed by a 2 h reoxygenation without substrate (control), or with either glucose, octanoic acid, oleic acid, or elaidic acid. During simulated ischemia, electromechanical function gradually disappeared while the cellular viability and mitochondrial function declined. During control simulated reperfusion, cardiomyocytes recovered near normal function but a significant reduction in the action potential amplitude and rate persisted. The addition of glucose or oleic acid during simulated reperfusion promoted a faster, better and sustain functional recovery. Amongst the fatty acids, the functional recovery was slower with elaidic and octanoic acids as compared with oleic acid. The mitochondrial function was better improved during simulated reperfusion with glucose than with the tested fatty acids, among which elaidic acid was the less unfavourable. Paradoxically, the addition of whichever substrate during simulated reperfusion tended to worsen the cellular viability. Thus, cardiomyocytes recovery strongly relies on the characteristics of the substrate supplied at the onset of simulated reperfusion: glucidic or lipidic nature, chain-length, insaturation degree. Moreover, these data suggest that defining the appropriateness of a given substrate for the post-ischemic cardiomyocyte recovery is closely related to the functional and the biological endpoints in consideration.
Tissier
Cindy
C
Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology, IFR 100, Institute of Cardiovascular Research, University Hospital Center, Dijon, France.
Vandroux
David
D
Devillard
Lisa
L
Brochot
Amandine
A
Moreau
Daniel
D
Rochette
Luc
L
Athias
Pierre
P
D000818:Animals; D000831:Animals, Newborn; D000959:Antihypertensive Agents / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism; D002210:Caprylates / Q000494:pharmacology*; D015687:Cell Hypoxia; D005947:Glucose / Q000494:pharmacology*; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism*; D019301:Oleic Acid / Q000494:pharmacology*; D009829:Oleic Acids; D010100:Oxygen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013379:Substrate Specificity; D013549:Sweetening Agents / Q000494:pharmacology
D000959:Antihypertensive Agents; D015415:Biomarkers; D002210:Caprylates; D009829:Oleic Acids; D013549:Sweetening Agents; D019301:Oleic Acid; C011459:elaidic acid; D005947:Glucose; C031492:octanoic acid; D010100:Oxygen